vs
AVINO SILVER & GOLD MINES LTD（ASM）与SUTRO BIOPHARMA, INC.（STRO）财务数据对比。点击上方公司名可切换其他公司
AVINO SILVER & GOLD MINES LTD的季度营收约是SUTRO BIOPHARMA, INC.的1.8倍（$21.0M vs $11.6M），AVINO SILVER & GOLD MINES LTD同比增速更快（44.0% vs -21.4%），过去两年AVINO SILVER & GOLD MINES LTD的营收复合增速更高（51.1% vs -5.4%）
阿维诺金银矿业有限公司是一家加拿大矿业企业，主要从事银、金、铜等贵金属及基本金属的勘探、开发与生产，核心运营资产为位于墨西哥杜兰戈州的旗舰阿维诺矿区，产品供应全球大宗商品市场。
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
ASM vs STRO — 直观对比
营收规模更大
ASM
是对方的1.8倍
$11.6M
营收增速更快
ASM
高出65.3%
-21.4%
两年增速更快
ASM
近两年复合增速
-5.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0M | $11.6M |
| 净利润 | $7.7M | — |
| 毛利率 | 47.1% | — |
| 营业利润率 | — | — |
| 净利率 | 36.6% | — |
| 营收同比 | 44.0% | -21.4% |
| 净利润同比 | 558.9% | 35.4% |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMSTRO
| Q4 25 | — | $11.6M | ||
| Q3 25 | $21.0M | $9.7M | ||
| Q2 25 | $21.8M | $63.7M | ||
| Q1 25 | $18.8M | $17.4M | ||
| Q4 24 | — | $14.8M | ||
| Q3 24 | $14.6M | $8.5M | ||
| Q2 24 | $14.8M | $25.7M | ||
| Q1 24 | $12.4M | $13.0M |
净利润ASMSTRO
| Q4 25 | — | — | ||
| Q3 25 | $7.7M | $-56.9M | ||
| Q2 25 | $2.9M | $-11.5M | ||
| Q1 25 | $5.6M | $-76.0M | ||
| Q4 24 | — | $-72.4M | ||
| Q3 24 | $1.2M | $-48.8M | ||
| Q2 24 | $1.2M | $-48.0M | ||
| Q1 24 | $599.0K | $-58.2M |
毛利率ASMSTRO
| Q4 25 | — | — | ||
| Q3 25 | 47.1% | — | ||
| Q2 25 | 46.9% | — | ||
| Q1 25 | 56.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 39.1% | — | ||
| Q2 24 | 31.8% | — | ||
| Q1 24 | 18.9% | — |
营业利润率ASMSTRO
| Q4 25 | — | — | ||
| Q3 25 | — | -499.9% | ||
| Q2 25 | — | -5.2% | ||
| Q1 25 | — | -393.8% | ||
| Q4 24 | — | -440.7% | ||
| Q3 24 | — | -797.2% | ||
| Q2 24 | — | -189.4% | ||
| Q1 24 | — | -435.0% |
净利率ASMSTRO
| Q4 25 | — | — | ||
| Q3 25 | 36.6% | -586.6% | ||
| Q2 25 | 13.1% | -18.0% | ||
| Q1 25 | 29.8% | -436.6% | ||
| Q4 24 | — | -489.2% | ||
| Q3 24 | 8.0% | -572.6% | ||
| Q2 24 | 8.4% | -186.8% | ||
| Q1 24 | 4.8% | -447.5% |
每股收益（稀释后）ASMSTRO
| Q4 25 | — | — | ||
| Q3 25 | $0.05 | $-0.67 | ||
| Q2 25 | $0.02 | $-0.14 | ||
| Q1 25 | $0.04 | $-0.91 | ||
| Q4 24 | — | $-27.63 | ||
| Q3 24 | $0.01 | $-0.59 | ||
| Q2 24 | $0.01 | $-0.59 | ||
| Q1 24 | $0.00 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.3M | $141.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $182.1M | $-132.5M |
| 总资产 | $221.9M | $173.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASMSTRO
| Q4 25 | — | $141.4M | ||
| Q3 25 | $57.3M | $167.6M | ||
| Q2 25 | $37.3M | $205.1M | ||
| Q1 25 | $26.6M | $249.0M | ||
| Q4 24 | — | $316.9M | ||
| Q3 24 | $7.8M | $388.3M | ||
| Q2 24 | $5.3M | $375.6M | ||
| Q1 24 | $3.5M | $267.6M |
股东权益ASMSTRO
| Q4 25 | — | $-132.5M | ||
| Q3 25 | $182.1M | $-87.3M | ||
| Q2 25 | $144.8M | $-32.1M | ||
| Q1 25 | $132.3M | $-25.8M | ||
| Q4 24 | — | $44.6M | ||
| Q3 24 | $114.5M | $111.2M | ||
| Q2 24 | $112.2M | $152.2M | ||
| Q1 24 | $107.8M | $98.0M |
总资产ASMSTRO
| Q4 25 | — | $173.8M | ||
| Q3 25 | $221.9M | $209.7M | ||
| Q2 25 | $174.7M | $262.4M | ||
| Q1 25 | $157.7M | $321.4M | ||
| Q4 24 | — | $387.2M | ||
| Q3 24 | $135.4M | $451.8M | ||
| Q2 24 | $133.7M | $489.0M | ||
| Q1 24 | $128.6M | $403.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.3M | $-177.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.08× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASMSTRO
| Q4 25 | — | $-177.2M | ||
| Q3 25 | $8.3M | $-38.2M | ||
| Q2 25 | $8.3M | $-44.7M | ||
| Q1 25 | $758.0K | $-67.9M | ||
| Q4 24 | — | $-71.7M | ||
| Q3 24 | $4.1M | $-64.5M | ||
| Q2 24 | $1.1M | $9.5M | ||
| Q1 24 | $2.3M | $-64.7M |
现金转化率ASMSTRO
| Q4 25 | — | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.55× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 3.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
